limb occlusion, aneurysm sac enlargement, and planned perioperative adjunctive maneuvers rate.
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Juxtarenal Endovascular Therapy With Fenestrated and Branched Stent Grafts After Previous Infrarenal Repair
Objectives: The treatment strategy for proximal aortic pathology or type I endoleak after previous infrarenal repair has traditionally been open surgery. As endovascular treatment options with fenestrated and branched stent grafts increasingly rival open surgery for juxtarenal and pararenal aortic aneurysms, secondary proximal repair may similarly be performed endovascularly. Fenestrated stent grafts are individually tailored to each patient, while a more readily available "off-theshelf" device branched stent graft is often suitable in more urgent settings.
Methods: All patients who had undergone reoperations with a proximal fenestrated or branched cuff after previous infrarenal endovascular or open repair from two tertiary referral centers between 2002 and 2015 were included in the analysis. Patients were retrospectively enrolled in a digital database. Data were collected from record review and digital imaging.
Results: There were 41 patients treated, 35 (85%) men and six (14%) women. The indications for proximal endovascular repair were type I endoleak (59%), proximal aneurysm formation (32%), and stent graft migration (10%). Median follow-up time was 31 months (range, 3-120 months). There were 32 patients (78%) who received a fenestrated cuff, and branched stent grafts were used in eight patients (19%). The majority of grafts had three (46.3%) or four (48.8%) fenestrations or branches. Mean procedure time was 338 minutes. Technical success was accomplished in 91% of patients. In two patients, the celiac trunk occluded, in one patient the hepatic artery was overstented, and in one patient a renal artery could not be cannulated. Median hospital stay was 5.5 days (range, 2-57 days). Nine patients (22%) suffered major complications. The 30-day mortality was 0%, and 1-year mortality was 5%. One patient died of an aneurysm-related cause during the study period.
Conclusions: An endovascular approach with fenestrated or branched stent grafts for treatment for proximal endoleak, proximal aneurysm formation, or pseudoaneurysms after previous infrarenal repair seems to be a valid alternative to open surgery. Objectives: We investigated the degree to which the volume of contrast used during an endovascular aneurysm repair (EVAR) predicts postprocedural short and long-term renal dysfunction.
Methods: A review of 101 patients from 2012 to 2016 was performed. Volume of contrast (Iopamidol 300) used during EVAR, as well as, preoperative and postoperative renal function at 24 hours, 48 to 72 hours, 1 to 3 months, 6 months, 1 year, and 2 years was determined. Multivariate analyses were performed to examine the relationship between chronic kidney disease (CKD) progression and volume of contrast used, adjusting for preoperative renal function and comorbidities, including obesity, cardiac comorbidities, preoperative renal insufficiency, diabetes, gender, hypertension, hyperlipidemia, smoking, and age at surgery.
Results: The mean (standard deviation) age was 74.4 6 8.9 years, and 80 (78.4%) patients were male. There was no significant difference in intraoperative contrast media use based on preoperative renal function status with the patients with normal preoperative renal function receiving mean 204.2 6 97.8 mL of contrast and patients with preoperative renal insufficiency receiving mean 188.6 6 104.1 mL of contrast. Comorbidity data were gathered and accounted for in subsequent analysis. Preoperatively, 51 patients had normal kidney function and 50 had renal insufficiency. Of the 50 patients with preoperative renal insufficiency, 45 had CKD stage 1, 4 had CKD stage 2, and 1 had stage 3. For every additional 50 mL of contrast, patients were 72.3% more likely to progress one CKD stage at 48 to 72 hours postprocedure (P < .001), 56.9% more likely at 1 to 3 months (P ¼ .002), 53.0% more likely at 6 months (P ¼ .002), 82.3% more likely at 1 year (P < .001), and 77.7% more likely at 2 years (P < .001). For patients with preoperative renal insufficiency, every additional 50 mL of contrast was associated with a 68.7% increase in the odds of a CKD stage progression at 48 to 72 hours (P ¼ .01) and a 49.7% increase at 2 years (P ¼ .05). Within 3 years post-EVAR, 20% of patients progressed at least one full CKD stage, 17% dropped one CKD stage, and 3% dropped two CKD stages. Ultimately, four patients, two initially at CKD stage 1, developed end-stage renal disease.
Conclusions: Our findings suggest the volume of contrast used during EVAR significantly predicts progression of CKD. Additionally, conservative contrast administration is essential to kidney health and contrast alternatives should be explored.
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